-

12:56:50 PM

LIVE Real Time MBRX Stock Market News

MBRX - Moleculin Biotech Inc

04/14/21 7:35 AM

Nasdaq : MBRX

Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma

Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced today that the U.S. Food and Drug

RHEA-AI

very positive

04/06/21 7:30 AM

Nasdaq, NYSE : MBRX, IQV

Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the engagement of IQVIA Biotech, a contract

RHEA-AI

neutral

03/30/21 7:30 AM

Nasdaq : MBRX

Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration

RHEA-AI

very positive

03/24/21 7:30 AM

Nasdaq : MBRX

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the year ended

RHEA-AI

positive

03/09/21 7:30 AM

Nasdaq : MBRX

Moleculin to Participate in Four Upcoming Healthcare Conferences

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will be presenting

RHEA-AI

neutral

02/10/21 4:15 PM

Nasdaq : MBRX

Moleculin Announces Full Exercise of Over-Allotment Option

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the underwriters of its public

RHEA-AI

neutral

02/08/21 7:30 AM

Nasdaq : MBRX

Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the Agencja Badan Medycznych (The Medical

RHEA-AI

neutral

02/03/21 8:30 AM

Nasdaq : MBRX

Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the pricing of an underwritten public

RHEA-AI

neutral

02/02/21 4:22 PM

Nasdaq : MBRX

Moleculin Announces Proposed Underwritten Public Offering

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it intends to offer and sell shares of

RHEA-AI

neutral

02/02/21 7:30 AM

Nasdaq : MBRX

Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a preclinical study in animals demonstrated

RHEA-AI

neutral